About Prussian blue insoluble formulations:
- It is one of the critical medicines listed by the World Health Organisation for radiological and nuclear emergencies.
- It was developed under the Technology Development Fund (TDF).
The drug has been developed based on the technology of the Institute of Nuclear Medicine and Allied Sciences (INMAS), Delhi, a laboratory of the DRDO.
- The formulations are used for the decontamination of Cesium and Thallium.
- The manufacturing and marketing licenses for the commercial use of the drug have been granted to Scott-Edil Pharmacia Limited, Himachal Pradesh, and Skanttr Lifescience, Gujarat, by DCGI.
- The drug will be available under the trade name of Pru-DecorpTM and PruDecorp-MG.
What is the Technology Development Fund (TDF)?
- It has been established to promote self-reliance in defense technology as a part of the 'Make in India' initiative.
- It is a program of the Ministry of Defence executed by DRDO meeting the requirements of Tri-Services, Defence Production, and DRDO.
- It supports the indigenous development of components, products, systems, and technologies by MSMEs and start-ups.
- Funding:
- The project cost of up to INR 10 Cr will be considered for funding, subject to a maximum of 90% of the total project cost.
- The funding will be through the provision of grants to the industry.
